Construction of Predictive Models for Cancer-specific Survival of Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Results from a Multicenter Retrospective Study

被引:6
|
作者
Nishiyama, Naotaka [1 ]
Kitamura, Hiroshi [1 ]
Hotta, Hiroshi [2 ]
Takahashi, Atsushi [3 ]
Yanase, Masahiro [4 ]
Itoh, Naoki [5 ]
Tachiki, Hitoshi [6 ]
Miyao, Noriomi [7 ]
Matsukawa, Masanori [8 ]
Kunishima, Yasuharu [9 ]
Taguchi, Keisuke [10 ]
Masumori, Naoya [1 ]
机构
[1] Sapporo Med Univ, Dept Urol, Sch Med, Sapporo, Hokkaido 0608543, Japan
[2] Asahikawa Red Cross Hosp, Dept Urol, Asahikawa, Hokkaido, Japan
[3] Hakodate Goryoukaku Hosp, Dept Urol, Hakodate, Hokkaido, Japan
[4] Sunagawa City Med Ctr, Dept Urol, Sunagawa, Japan
[5] NTT East Japan Sapporo Hosp, Dept Urol, Sapporo, Hokkaido, Japan
[6] Steel Mem Muroran Hosp, Dept Urol, Muroran, Hokkaido, Japan
[7] Muroran City Gen Hosp, Dept Urol, Muroran, Hokkaido, Japan
[8] Takikawa Municipal Hosp, Dept Urol, Takikawa, Hokkaido, Japan
[9] Hokkaido Social Work Assoc Obihiro Hosp, Dept Urol, Obihiro, Hokkaido, Japan
[10] Oji Gen Hosp, Dept Urol, Tomakomai, Japan
关键词
non-muscle-invasive bladder cancer; bacillus Calmette-Guerin; BCG failure classification; UROTHELIAL CARCINOMA; PROGNOSTIC-FACTORS; RISK; MANAGEMENT; FAILURE; TUMORS; PROGRESSION; RECURRENCE; THERAPY; DISEASE;
D O I
10.1093/jjco/hyu119
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aims of this study were to clarify the prognostic factors and to validate the bacillus Calmette-Guerin failure classification advocated by Nieder et al. in patients with non-muscle-invasive bladder cancer who had intravesical recurrence after bacillus Calmette-Guerin therapy. Methods: Data from 402 patients who received intravesical bacillus Calmette-Guerin therapy between January 1990 and November 2011 were collected from 10 institutes. Among these patients, 187 with bacillus Calmette-Guerin failure were analyzed for this study. Results: Twenty-nine patients (15.5%) were diagnosed with progression at the first recurrence after bacillus Calmette-Guerin therapy. Eighteen (62.1%) of them died of bladder cancer. A total of 158 patients were diagnosed with non-muscle-invasive bladder cancer at the first recurrence after bacillus Calmette-Guerin therapy. Of them, 23 (14.6%) underwent radical cystectomy. No patients who underwent radical cystectomy died of bladder cancer during the follow-up. On multivariate analysis of the 135 patients with bladder preservation, the independent prognostic factors for cancer-specific survival were age (>= 70 [P = 0.002]), tumor size (>= 3 cm [P = 0.015]) and the Nieder classification (bacillus Calmette-Guerin refractory [P < 0.001]). In a subgroup analysis, the estimated 5-year cancer-specific survival rates in the groups with no positive, one positive and two to three positive factors were 100, 93.4 and 56.8%, respectively (P < 0.001). Conclusions: Patients with stage progression at the first recurrence after bacillus Calmette-Guerin therapy had poor prognoses. Three prognostic factors for predicting survival were identified and used to categorize patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin into three risk groups based on the number of prognostic factors in each one.
引用
收藏
页码:1101 / 1108
页数:8
相关论文
共 50 条
  • [41] The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin
    Brooks, Nathan A.
    Kokorovic, Andrea
    Xiao, Lianchen
    Matulay, Justin T.
    Li, Roger
    Ranisinghe, Weranja K. B.
    Nagaraju, Supriya
    Shen, Yu
    Gao, Jianjun
    Navai, Neema
    Dinney, Colin P. N.
    Grossman, H. Barton
    Kamat, Ashish M.
    BJU INTERNATIONAL, 2021, 128 (01) : 65 - 71
  • [42] Efficacy and toxicity of intravesical Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer
    Matsuoka, Yuki
    Taoka, Rikiya
    Kohashiguchi, Kana
    Tohi, Yoichiro
    Miyauchi, Yasuyuki
    Kato, Takuma
    Tsunemori, Hiroyuki
    Ueda, Nobufumi
    Sugimoto, Mikio
    CURRENT UROLOGY, 2021, 15 (01) : 16 - 21
  • [43] The EORTC Tables Overestimate the Risk of Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: External Validation of the EORTC Risk Tables
    Fernandez-Gomez, Jesus
    Madero, Rosario
    Solsona, Eduardo
    Unda, Miguel
    Martinez-Pineiro, Luis
    Ojea, Antonio
    Portillo, Jose
    Montesinos, Manuel
    Gonzalez, Marcelino
    Pertusa, Carlos
    Rodriguez-Molina, Jesus
    Emilio Camacho, Jose
    Rabadan, Mariano
    Astobieta, Ander
    Isorna, Santiago
    Muntanola, Pedro
    Gimeno, Anabel
    Blas, Miguel
    Antonio Martinez-Pineiro, Jose
    EUROPEAN UROLOGY, 2011, 60 (03) : 423 - 430
  • [44] Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Guerin
    Packiam, Vignesh T.
    Johnson, Scott C.
    Steinberg, Gary D.
    CANCER, 2017, 123 (03) : 390 - 400
  • [45] Bacillus Calmette-Guerin Without Maintenance Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer
    Herr, Harry W.
    Dalbagni, Guido
    Donat, Sherri M.
    EUROPEAN UROLOGY, 2011, 60 (01) : 32 - 36
  • [46] Maintenance Bacillus Calmette-Guerin Treatment of Non-muscle-invasive Bladder Cancer: A Critical Evaluation of the Evidence
    Ehdaie, Behfar
    Sylvester, Richard
    Herr, Harry W.
    EUROPEAN UROLOGY, 2013, 64 (04) : 579 - 585
  • [47] A Plea for Long-Term Surveillance in Bacillus Calmette-Guerin-Treated Non-Muscle-Invasive Bladder Cancer
    Meijer, Richard P.
    van Rhijn, Bas W. G.
    EUROPEAN UROLOGY, 2012, 61 (03) : 508 - 509
  • [48] Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data
    Tomida, Ryotaro
    Miyake, Makito
    Minato, Ryoei
    Sawada, Yuichiro
    Matsumura, Masafumi
    Iida, Kota
    Hori, Shunta
    Fukui, Shinji
    Ohyama, Chikara
    Miyake, Hideaki
    Hongo, Fumiya
    Taoka, Rikiya
    Kobayashi, Takashi
    Kojima, Takahiro
    Matsui, Yoshiyuki
    Nishiyama, Naotaka
    Kitamura, Hiroshi
    Nishiyama, Hiroyuki
    Fujimoto, Kiyohide
    Hashine, Katsuyoshi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (05) : 958 - 968
  • [49] Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma
    Miyake, Makito
    Tatsumi, Yoshihiro
    Matsumoto, Hiroaki
    Nagao, Kazuhiro
    Matsuyama, Hideyasu
    Inamoto, Teruo
    Azuma, Haruhito
    Yasumoto, Hiroaki
    Shiina, Hiroaki
    Fujimoto, Kiyohide
    BJU INTERNATIONAL, 2018, 121 (05) : 764 - 773
  • [50] The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
    Wo, Jennifer Y.
    Shipley, William U.
    Dahl, Douglas M.
    Coen, John J.
    Heney, Niall M.
    Kaufman, Donald S.
    Zietman, Anthony L.
    BJU INTERNATIONAL, 2009, 104 (02) : 179 - 183